论文部分内容阅读
本文应用血管紧张素Ⅱ（ＡＴⅡ）介导的肝动脉升压化疗栓塞（ＩＨＣＥ）对２１例原发性肝癌（ＰＬＣ）进行治疗。结果显示：（１）ＩＨＣＥ后肿瘤缩小５０％以上者占５７％（１２／２１），与非升压ＴＡＥ治疗２４例临床条件相匹配的ＰＬＣ相比，疗效显著提高（５７％：３３．４％，Ｐ＜０．０１）；（２）ＩＨＣＥ后二期手术切除８例肿瘤坏死率达８６％，而对照组５例二期手术肿瘤坏死率为６１％，两者相比差异显著（Ｐ＜０．０１），（３）ＩＨＣＥ治疗组未出现严重并发症。本研究结果表明应用ＡＴⅡ可提高ＴＡＥ的疗效和减少ＴＡＥ并发症的发生。
In this article, 21 patients with primary liver cancer (PLC) were treated with angiotensin II (ATII)-mediated hepato-arrestor chemoembolization (IHCE). The results showed that: (1) 57% of patients with tumor shrinkage after IHCE accounted for 57% (12/21), compared with PLC with 24 cases of non-rising TAE therapy, the curative effect was significantly improved (57%: 33.4) %, P<0.01); (2) The tumor necrosis rate in 8 cases after IHCE secondary resection was 86%, while the tumor necrosis rate in 5 cases in the control group was 61% in the second stage. There was a significant difference between the two groups (P<0.01). <0.01), (3) There was no serious complication in the IHCE treatment group. The results of this study indicate that using ATII can improve the efficacy of TAE and reduce the incidence of TAE complications.